Jan 22, 2020
Compound Lights up Brain Receptors in PET Scans
Dec 10, 2019
Kyowa Hakko's Sustamine® L-Alanyl-L-Glutamine is featured in True Athlete® in Latest Novel Sports Nutrition Blend
Dec 05, 2019
Biohaven Announces Issuance of Composition of Matter Patent on Troriluzole by the U.S. Patent and Trademark Office
Oct 28, 2019
Biohaven Completes Enrollment In Phase 3 Generalized Anxiety Disorder (GAD) Trial Of Troriluzole
Sep 11, 2019
Global and Chinese Market Glutamic Pyruvic Transaminase (GPT) Market Insights, 2014-2019 & 2019-2024 by Manufacturers, Product Type, Application, and Technology - ResearchAndMarkets.com
May 07, 2019
Liver Function Tests Market Size to Gain Owing to Increasing Occurrence of Liver Diseases & Rising Technological Enhancement in Diagnostic Devices: Radiant Insights, Inc.
May 07, 2019
Biohaven Advances Late Stage Clinical Programs And Novel Targets From Neuroinnovation Platforms
Dec 13, 2018
Sosei Heptares Starts New Clinical Development Program - First Subject Dosed in Phase I Study of HTL0014242, a Selective mGlu5 Negative Allosteric Modulator in Development to Treat Psychiatric and Neurological Disorders
Jul 24, 2018
Biohaven Receives FDA May Proceed Letter And Initiates Phase 2/3 Clinical Trial Of Trigriluzole (BHV-4157) In Alzheimer's Disease
Jun 08, 2018
Schizophrenia Frontier Pharma Report 2018: A Complex and Poorly Understood Disorder with Numerous Unmet Needs
May 17, 2018
Aptinyx Appoints Robert Hombach to Board of Directors
Mar 21, 2018
Aptinyx to Present at Needham & Company's 17th Annual Healthcare Conference
Mar 15, 2018
Aptinyx Presents Data on NMDA Receptor Modulator NYX-458 in a Preclinical Model of Parkinson's Cognitive Impairment at the AAT-AD/PD Focus Meeting 2018
Jan 18, 2018
Biohaven Announces Initiation Of Clinical Development For BHV-5000, A Novel Low-Trapping NMDA Antagonist
Jan 09, 2018
Relmada Therapeutics Announces Notice of Acceptance of Key Patent in Europe Covering NMDA Receptor Antagonist d-Methadone for Treatment of Psychiatric Symptoms
Dec 28, 2017
Aptinyx to Present at 36th Annual J.P. Morgan Healthcare Conference
Dec 18, 2017
Aptinyx Raises $70 Million in Series B Financing to Advance Growing Pipeline through Clinical Studies in Neurologic Disorders
Dec 07, 2017
Aptinyx Granted Fast Track Designation, Initiates Phase 1 for Second Clinical Candidate, NYX-783, in Post-Traumatic Stress Disorder
Dec 07, 2017
Aptinyx Bolsters Executive Leadership Team with Appointment of Andy Kidd as Chief Commercial Officer
Nov 14, 2017
Aptinyx to Present Preclinical Data for NMDA Receptor Modulators in Neurologic Disorders at Neuroscience 2017